U.S. Congress legislation · 119th Congress
HB5160: Stem Cell Therapeutic and Research Reauthorization Act of 2025
Status: Passed one chamber, July 21, 2026
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
What the bill says
An act To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
From the amended text, July 21, 2026:
AN ACT To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. SECTION 1. Short title This Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2025 . SECTION 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program Section 379B of the Public Health Service Act ( 42 U.S.C. 274m ) is amended-- (1) by striking appropriated $31,009,000 and inserting the following: appropriated-- (1) $31,009,000 ; (2) in paragraph (1), as so inserted, by striking the period at the end and inserting ; and ; and (3) by adding at the end the following: (2) $33,009,000 for each of fiscal years 2027 through 2031. . SECTION 3. Cord blood inventory (a) In general Section 2(a) of the Stem Cell Therapeutic and Research Act of 2005 ( 42 U.S.C. 274k note) is amended by striking at least 150,000 new units of high-quality cord blood and inserting a sufficient supply, as determined by the Secretary, of high-quality cord blood units . (b) Application Section 2(c) of such Act ( 42 U.S.C. 274k note) is amended-- (1) in paragraph (2), by striking in perpetuity or ; and (2) by amending paragraph (5) to read as follows: (5) if the Secretary determines through an assessment, or through petition by the applicant, that a …
Sponsors
- Christopher Smith (R, HD-NJ-4) · primary sponsor
- Doris Matsui (D)
- Gus Bilirakis (R, HD-FL-12)
- Chellie Pingree (D, HD-001)
- Claudia Tenney (R, HD-024)
- Kweisi Mfume (D, HD-007)
- Michelle Fischbach (R, HD-007)
- Debbie Dingell (D, HD-006)
- Josh Gottheimer (D, HD-005)
- Robert Aderholt (R, HD-AL-4)
- Nicole Malliotakis (R, HD-011)
- Kathy Castor (D, HD-014)
Latest actions
- : Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
- : Motion to reconsider laid on the table Agreed to without objection.
- : On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- : Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- : DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
- : Considered under suspension of the rules. (consideration: CR H4642-4643)
- : Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- : Placed on the Union Calendar, Calendar No. 629.
- : Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- : Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
Subjects: Health programs administration and funding, Organ and tissue donation and transplantation, Cell biology and embryology, Biological and life sciences, Blood and blood diseases, Health
Common questions
- What is HB5160?
- HB5160 is a bill in Congress (119th Congress): Stem Cell Therapeutic and Research Reauthorization Act of 2025.
- What does HB5160 do?
- In its own words: An act To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
- What is the status of HB5160?
- Passed one chamber as of July 21, 2026. Latest action: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464. (July 21, 2026).
- Who sponsored HB5160?
- Christopher Smith (R, HD-NJ-4), with 11 co-sponsors.
- Where is the official record for HB5160?
- On the Congress website: https://www.congress.gov/bill/119th-congress/house-bill/5160
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.